Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States

Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States

Few peer-reviewed publications present real-world United States (US) data describing resource utilization and costs associated with herpes zoster (HZ) and postherpetic neuralgia (PHN). The primary objective of this analysis (GSK study identifier: HO-14–14270) was to assess direct costs associated wi...

Full description

Bibliographic Details
Main Authors: Juliana L. Meyers, Shweta Madhwani, Debora Rausch, Sean D. Candrilli, Girishanthy Krishnarajah, Songkai Yan
Format: Article
Language:English
Published: Taylor & Francis Group 2017-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
costs
herpes zoster
postherpetic neuralgia
managed care
retrospective claims analysis
Online Access:http://dx.doi.org/10.1080/21645515.2017.1324373

Internet

http://dx.doi.org/10.1080/21645515.2017.1324373

Similar Items